Patent ID: 7326727

Claim:
A method for the therapeutic therapy of colorectal cancer, small cell lung cancer, non-small cell lung cancer, breast cancer, renal cancer, or gastric cancer, comprising administering to a patient suffering therefrom a pharmaceutically effective amount of a compound of formula I or a pharmaceutically acceptable salt or prodrug thereof: wherein Q is (CH 2 ) m (CH(R 1 )) n (CH 2 ) p ; n is 0 or 1; m and p are, independently, 0, 1 or 2; R 1 is hydrogen, C 1-6 alkyl, C 2-6 alkenyl or C 3-6 alkynyl; R 2 is hydrogen, halogen, C 1-6 alkyl optionally substituted by hydroxy or C 1-6 alkoxy, or phenyl optionally substituted by one or more substituents selected from halogen, C 1-6 alkyl, CF 3 , OCF 3 , OR 6 , CN and methylenedioxo; R 3 , R 4 and R 5 are, independently, hydrogen, halogen, C 1-6 alkyl optionally substituted by hydroxy or C 1-6 alkoxy, CF 3 , OR 6 , COR 7 , NHCOR 8 , NHCONHR 8 , NHSO 2 R 8 , CONHR 9 , CN, SO 2 R 8 or NR 10 R 11 ; R 6 is hydrogen, C 2-6 alkenyl, C 3-6 alkynyl, C 1-6 alkyl optionally substituted by hydroxy or C 1-6 alkoxy, aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF 3 , OCF 3 , CN, C 1-6 alkyl, C 1-6 alkoxy and methylenedioxo; R 7 is C 1-6 alkyl, OR 6 or phenyl optionally substituted by one or more substituents selected from halogen, CF 3 , OCF 3 , CN, C 1-6 alkyl, C 1-6 alkoxy and NHCOR 8 ; R 8 is C 1-6 alkyl, C 2-6 alkenyl, or C 1-6 alkoxy, any of which is optionally substituted by aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF 3 , OCF 3 , OR 6 , CN, C 1-6 alkyl, methylenedioxo and NR 10 R 11 ; C 3-6 cycloalkyl, wherein the cycloalkyl ring optionally contains up to two heteroatoms selected from NR 12 , S and O; or aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF 3 , OCF 3 , OR 6 , CN, C 1-6 alkyl, methylenedioxo and NR 10 R 11 ; R 9 is C 1-6 alkyl, C 1-6 alkylphenyl, or phenyl, wherein the alkyl groups are optionally interrupted by oxygen and wherein the phenyl groups are optionally substituted by one or more substituents selected from halogen, C 1-6 alkyl, CF 3 , OCF 3 , CN, C 1-6 alkoxy and methylenedioxo; R 10 and R 11 are, independently, hydrogen or C 1-6 alkyl, or together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclic group which optionally contains an additional heteroatom selected from NR 12 , O and S; and R 12 is hydrogen or C 1-6 alkyl.